CAR-T therapy, which uses patients’ genetically modified immune cells to fight cancer, has been on the market for more than a year. However, Medicare is still establishing a payment plan for the therapy, and private insurers often enter into one-off billing arrangements with hospitals that take months to settle.
CAR-T therapies cost hundreds of thousands of dollars and hospitals still don’t know if they’ll be reimbursed enough to cover their expenses.
Virginia Commonwealth University Massey Cancer Center in Richmond has been treating patients with CAR-T therapy since August.
Penny Trentham, vice president of managed care and payer relations at VCU Health, told STAT that the hospital is still waiting for for insurers to pay the bill for the four patients they’ve treated with CAR-T.
“We’ve not been paid on those, and it’s been several months,” Ms. Trentham told STAT. “It doesn’t mean there’s a problem, necessarily. These are very complex claims. But we have not been paid.”
She added that VCU Health is missing about $1 million from unpaid CAR-T bills and isn’t sure if the hospital will even break even when insurers do pay.
The uncertainty comes because this treatment is new and at such a high price point.
“It’s just really hard right now, and I think everybody’s asking for specific answers, but until we get more experience with this treatment protocol, it’s hard to say that we would be willing to accept as a defined payment term,” Ms. Trentham told STAT. “Literally, you should do hundreds of cases before you draw a conclusion.”
Read the full report here.
More articles on pharmacy:
Bristol-Myers urges shareholders to support Celgene takeover
Novartis to pay $23M to settle claims it used charity payments as kickbacks
Martin Shkreli reportedly running his pharma company from prison
